Locally Advanced Breast Cancer Clinical Trial
Official title:
Treatment Selection and Efficacy of Locally Advanced Breast cancer-a Prospective Randomized Controlled Study
The goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer（LABC). Patients with LABC will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. The main comparison was between the disease-free survival (DFS) of two groups of patients, with the secondary study endpoint being overall survival (OS); Five year survival; Local recurrence or distant metastasis rate.
Local advanced breast cancer was enrolled in the Department of Breast Surgery of Peking Union Medical College Hospital and Beijing Cooperation Hospital according to the criteria for patient inclusion. It is estimated that 50 patients will be enrolled. Randomly divide patients into two groups. The plan for Group A (experimental group, 25 cases) is "surgery+systematic treatment"; The plan for Group B (control group, 25 cases) is "neoadjuvant therapy+surgery+systematic treatment". Based on the previously obtained patient personal information, treatment related information, tumor tissue/blood sample test results, statistical analysis was conducted to explore the impact of different treatment strategies for locally advanced breast cancer on the survival and prognosis of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01048918 -
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
|
||
| Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
| Terminated |
NCT01837563 -
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
|
N/A | |
| Recruiting |
NCT03978663 -
Three Fraction Radiation to Induce Immuno-Oncologic Response
|
N/A | |
| Active, not recruiting |
NCT04352777 -
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06064812 -
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
|
Phase 1 | |
| Recruiting |
NCT05963997 -
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02595762 -
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
|
||
| Active, not recruiting |
NCT02965950 -
The p53 Breast Cancer Trial
|
Phase 2 | |
| Completed |
NCT01785992 -
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
|
Phase 2 | |
| Completed |
NCT00764036 -
Study of Artesunate in Metastatic Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT05021900 -
Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT04088032 -
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
|
Early Phase 1 | |
| Completed |
NCT00455273 -
Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
|
||
| Terminated |
NCT04042051 -
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05582499 -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05749016 -
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
|
Phase 2 |